Coelho Rogerio Vivaldi - 21 Jul 2023 Form 4 Insider Report for Sigilon Therapeutics, Inc.

Role: PRESIDENT AND CEO, Director
Signature: /s/ Matthew Kowalsky, Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 21 Jul 2023
Net transactions value: +$106,359
Form type: 4
Filing time: 24 Jul 2023, 19:44:36 UTC
Previous filing: 21 Jun 2023
Next filing: 11 Aug 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SGTX	Common Stock	Options Exercise	$106,359	+5,528	+86%	$19.24^*	11,963	21 Jul 2023	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SGTX	Stock Option (Right to Buy)	Options Exercise	$0	-5,528	-31%	$0.000000	12,163	21 Jul 2023	Common Stock	5,528	$19.24	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Includes 786 shares acquired by the Reporting Person pursuant to the Issuer's 2020 Employee Stock Purchase Plan ("ESPP") for the purchase periods from October 1, 2021 to March 31, 2023. In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock . These transaction are exempt under Rule 16b-3(c).
F2	Effective May 22, 2023, the Issuer effected a 1-for-13 reverse stock split (the "Reverse Split") of its issued and outstanding shares of Common Stock. Cash was paid in lieu of any fractional shares resulting from the Reverse Split. The Reporting Person's beneficial ownership in this Form 4 has been adjusted for the Reverse Split.
F3	The option vested as to 25% of the underlying shares of common stock on February 18, 2023, the first anniversary of the vesting commencement date, and at a rate of 6.25% of the underlying shares thereafter on the first day of each quarter following such date until the option is fully vested.